The Innovative Medicines Accelerator turns its focus on COVID-19

Plans for Stanford’s new Innovative Medicines Accelerator arose before the COVID-19 pandemic struck, but now its programs are focused entirely on helping faculty generate and test new medicines to slow the spread of the disease.

Click to view original post